Aller au contenu principal
xMedica

NCT07326709ClinicalTrials.gov

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

A Randomized, Placebo-controlled, Double-blind Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518…

Phase 3770 participants recherchés117 sites27 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-01-08; recorded start 2026-03-24
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1147 other studies in this databaseCounted from the lead sponsor named in the record (Novartis Pharmaceuticals)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 41 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 770 participants (target), run at 117 sites, across 27 countries.

How this score is built
  • Enrolment28/40

    770 participants (target)

  • Site count19/25

    41 sites

  • Country count12/15

    9 countries

  • Planned duration9/10

    Planned over about 50 months

  • Sponsor scale10/10

    Novartis Pharmaceuticals has led 1,104 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.

This study will have a variable double-blind treatment duration of up to 36 months. As part of the study design, not every participant will complete 36 months of treatment. The study consists of 3 periods: * Screening Period: A period of up to 42-days to assess participants eligibility * Double-blind Treatment Period: This period will have variable individual treatment duration, up to 36 months. The double-blind treatment period concludes when ≥50% patients complete Month 36. The maximum treatment duration for an individual participant is 36 months. * Safety Follow-up Period: A period consisting of one safety follow-up visit, conducted on site or by phone call, for all participants not continuing treatment in the separate open-label extension study or discontinuing early. The visit/phone call will take place 30 days after End of Study (EOS)

Affections

  • Huntington Disease

Éligibilité

Éligibilité
SexeTous
Âges21 Years – 70 Years
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Inclusion Criteria: * Signed informed consents must be obtained prior to participation in the study * Ambulatory male or female participants between 21 to 70 years of age, inclusive, on the day of Informed Consent signature * Genetically confirmed HD diagnosis with a cytosine-adenine-guanine (CAG) repeat length of 40 or above. Participants must have prior genetic confirmation and known CAG repeat length obtained prior to screening. * Meets all of the following criteria: * UHDRS IS score ≥90 * UHDRS TFC score = 13 * UHDRS TMS score = 7-25, inclusive * CAP100 ≥ 70 Calculation: CAP = Age at study entry × (CAG length - 30) / 6.49 Exclusion Criteria: * History of gene therapy or cell transplantation or any other experimental brain surgery for the treatment of HD * Serologic evidence for active viral hepatitis as indicated by: * positive anti-HBc IgM * positive anti-HBc IgG confirmed by positive HBsAg and/or HBV DNA * positive HCV ab test confirmed by positive HCV RNA * Immunodeficiency diseases, including a positive human immunodeficiency virus (HIV) test result * History or current diagnosis of ECG or cardiac abnormalities indicating significant risk of safety for participants such as: * Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second- or third-degree AV block without a pacemaker * History of familial long QT syndrome or known family history of Torsade de Pointes * Women of childbearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral salpingectomy at least six weeks before taking study treatment. In the case of oophorectomy alone, the reproductive status of the woman needs to have been confirmed by follow-up hormone level assessment. o WOCBP are excluded unless they are using highly effective methods of contraception (failure rate \< 1% per year) while taking study treatment and for 8 months after stopping study treatment. * Pregnant or nursing (breastfeeding) women Other protocol defined inclusion/exclusion criteria may apply

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhasePhase 3
RépartitionRandomisée
Modèle d'interventionPARALLEL
Objectif principalTREATMENT
InsuQUADRUPLE (4)
Recrutement770 participants recherchés

Promoteur et collaborateurs

  • Novartis Pharmaceuticals Promoteur

Groupes et interventions

  • VotoplamEXPERIMENTAL

    Votoplam (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo)

  • PlaceboPLACEBO_COMPARATOR

    Placebo (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo)

Interventions

  • Médicament Placebo

    Placebo

  • Médicament Votoplam (blinded)

    Votoplam (blinded) active treatment

Critères de jugement

  1. Critère de jugement principal

    Change from Baseline in cUHDRS score

    The Composite Unified Huntingtons Disease Ratings Scale (cUHDRS) is an improved composite measure to assess multi-domain clinical progression in HD. The cUHDRS is a combined weighted score of measures of motor function (TMS), cognition (SDMT and SWRT) and overall functional capacity (TFC): cUHDRS = \[(TFC-10.4)/1.9 - (TMS-29.7)/14.9 + (SDMT-28.4)/11.3 + (SWRT - 66.1)/20.1\] + 10. In conjunction with one another, these measures provide a comprehensive, sensitive and specific tool for monitoring disease progression, with lower scores indicating more severe disease. cUHDRS score range from -8 to 25.

    Délai Baseline, Month 36

  2. Critère de jugement secondaire

    Change from Baseline in UHDRS-TFC

    The UHDRS-Total Functional Capacity (TFC) focuses on the Investigator's assessment of the participant's capacity to perform a range of activities including occupation, finances, self-care, domestic chores and activities of daily living. The responses are derived from interview with the participant and/or companion, if applicable. Scores range from 0 to 13, with higher scores representing better functioning.

    Délai Baseline, Month 36

  3. Critère de jugement secondaire

    Change from Baseline in UHDRS-IS

    The UHDRS-Independence Scale (IS) measures a patient's overall level of functional independence in activities of daily living. It provides a single score ranging from 10 (total dependence/bedbound) to 100 (no special care needed) in intervals of 10, with higher scores indicating better functioning. Scores can also be assigned in increments of 5 for intermediate levels of function.

    Délai Baseline, Month 36

  4. Critère de jugement secondaire

    The time to decline in TFC score by at least one or IS score by at least 10

    The UHDRS-Total Functional Capacity (TFC) focuses on the Investigator's assessment of the participant's capacity to perform a range of activities including occupation, finances, self-care, domestic chores and activities of daily living. The responses are derived from interview with the participant and/or companion, if applicable. Scores range from 0 to 13, with higher scores representing better functioning. The UHDRS-Independence Scale (IS) measures a patient's overall level of functional independence in activities of daily living. It provides a single score ranging from 10 (total dependence/bedbound) to 100 (no special care needed) in intervals of 10, with higher scores indicating better functioning. Scores can also be assigned in increments of 5 for intermediate levels of function.

    Délai Baseline to end of treatment up to 36 months

  5. Critère de jugement secondaire

    Change from Baseline in UHDRS-TMS

    The UHDRS-Total Motor Score (TMS) is the cumulative sum of the individual motor ratings obtained during the administration of the motor assessment portion of the UHDRS. It includes items related to eye movements, speech, limb movements (including hand taps and pronation-supination), dystonia, chorea, and gait/balance. Scores range from 0 to 124, with higher scores indicating greater motor impairment.

    Délai Baseline, Month 36

  6. Critère de jugement secondaire

    Change from Baseline in SDMT

    The Symbol Digit Modality Test (SDMT) is used to assess attention, working memory, psychomotor speed and visual perceptual processing. Participants are presented with a translation key of specific numbers paired with unique abstract symbols. Below the translation key is an array of symbols paired with empty spaces, the participant's task is to match the number for each symbol as quickly as possible in a given time frame. Scores are based on number of correctly paired items and range from 0 to 110, with higher scores representing better performance.

    Délai Baseline, Month 36

  7. Critère de jugement secondaire

    Change from Baseline in SWRT

    The Stroop Word Reading Test (SWRT) is a measure of processing and psychomotor speed. Participants are presented with a list or words (color names) printed in black ink and asked to read aloud as many words as possible within a set timeframe. Scores are based on the number of words read correctly and range from 0 to 60, with higher scores representing better performance.

    Délai Baseline, Month 36

  8. Critère de jugement secondaire

    Percent change from Baseline in blood mHTT protein

    The mutant huntington protein (mHTT) which is detectable both in blood and cerebrospinal fluid (CSF), represents a reliable biomarker for HD due to its direct involvement in disease pathology. Blood mHTT is a direct product of the pathogenic HTT gene mutation and represents a proximal marker of Huntington's disease (HD) biology.

    Délai Baseline to steady state and up to 36 months in blood mHTT protein

  9. Critère de jugement secondaire

    Change from Baseline in serum NfL

    Serum Neurofilament light chain NfL is a component of the neuronal cytoskeleton, released into CSF and blood after neuro-axonal damage, serving as a marker of neurodegeneration and disease progression in HD.

    Délai Baseline, Month 36

  10. Critère de jugement secondaire

    Incidence and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and TEAEs leading to participant withdrawal

    Number of participants with AEs and SAEs, including notable findings on physical examination, changes in vital signs, laboratory parameters, ECG, etc.

    Délai Baseline to up to 36 months

Dates

Dates
Date de début24 mars 2026 (réelle)
Achèvement principal2 avril 2030 (estimée)
Achèvement30 avril 2030 (estimée)
Première publication8 janvier 2026 (réelle)
Dernière mise à jour22 septembre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisseptembre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

117 sites sont en recrutement

Argentina

Argentina
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteBuenos AiresEn recrutement
Instituto Argentino de Investigación Neurológica (IADIN)CABABuenos AiresEn recrutement
Centro de Investigaciones Metabólicas (CINME)CABABuenos AiresEn recrutement
Novartis Investigative SiteCiudad deBuenos AiresEn recrutement

Australia

Australia
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteCaulfield SouthVictoriaEn recrutement
Novartis Investigative SiteWestmeadNew South WalesEn recrutement

Belgium

Belgium
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteLeuvenVlaams BrabantEn recrutement

Bulgaria

Bulgaria
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteSofiaEn recrutement
Novartis Investigative SiteSofiaEn recrutement

Canada

Canada
ÉtablissementVilleÉtat ou régionStatut
CUSM Montreal Neurological InstituteMontrealQuebecEn recrutement
Centre de recherche du CHUMMontrealQuebecEn recrutement
North York General HospitalNorth YorkOntarioEn recrutement

China

China
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteBeijingEn recrutement
Novartis Investigative SiteBeijingEn recrutement
The Second Xiangya Hospital of Central South UniversityChangshaHunanEn recrutement
West China Hospital of Sichuan UniChengduSichuanEn recrutement
Novartis Investigative SiteFuzhouFujianEn recrutement
Novartis Investigative SiteGuangzhouGuangdongEn recrutement
Novartis Investigative SiteGuangzhouGuangdongEn recrutement
The Second Affiliated Hosp Of Zhejiang Univ School Of MedicineHangzhouZhejiangEn recrutement
Novartis Investigative SiteShanghaiEn recrutement
Tongji Hos Affiliated Tongji Medical College of HuazhongWuhanHubeiEn recrutement

Colombia

Colombia
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteMedellínEn recrutement

Czechia

Czechia
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteBrnoEn recrutement
Novartis Investigative SitePragueEn recrutement

Denmark

Denmark
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteCopenhagenEn recrutement

France

France
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteAngersFranceEn recrutement
Novartis Investigative SiteMarseilleEn recrutement
Novartis Investigative SiteMontpellierEn recrutement

Germany

Germany
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteAachenEn recrutement
Novartis Investigative SiteBochumEn recrutement
Novartis Investigative SiteMünsterEn recrutement
Novartis Investigative SiteTübingenEn recrutement
Novartis Investigative SiteUlmEn recrutement

Hungary

Hungary
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteBudapestEn recrutement
Novartis Investigative SiteSzegedEn recrutement

Israel

Israel
ÉtablissementVilleÉtat ou régionStatut
Tel Aviv Sourasky Med Ctr IchilovTel AvivEn recrutement

Italy

Italy
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteBolognaBOEn recrutement
Novartis Investigative SiteBresciaBSEn recrutement
Novartis Investigative SiteMilanMIEn recrutement
Novartis Investigative SiteMilanMIEn recrutement

Japan

Japan
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteBunkyo KuTokyoEn recrutement
Novartis Investigative SiteKashiharaNaraEn recrutement
Novartis Investigative SiteSagamiharaKanagawaEn recrutement

Netherlands

Netherlands
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteLeidenSouth HollandEn recrutement
Novartis Investigative SiteMaastrichtLimburgEn recrutement

Poland

Poland
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteKrakowPOLEn recrutement

Portugal

Portugal
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteLisbonEn recrutement
Novartis Investigative SitePortoEn recrutement

Romania

Romania
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteBucharestEn recrutement

67 sites supplémentaires sont indiqués dans la fiche du registre.

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 22 septembre 2026

    Site ajouté

    35 sites added (117 total)

    82117

  2. 31 août 2026

    Site ajouté

    22 sites added (82 total)

    6082

  3. 11 août 2026

    Site ajouté

    9 sites added (60 total)

    5160

  4. 29 juillet 2026

    Site ajouté

    10 sites added (51 total)

    4151